Stay updated with breaking news from Amarin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.
Amarin (NASDAQ:AMRN – Get Rating) and Sanofi (OTCMKTS:SNYNF – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership. Earnings & Valuation This table compares Amarin and Sanofi’s top-line revenue, earnings […]
-- VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with Severe Hypertriglyceridemia (= 500 mg/dL) -- --
DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 -- Amarin Corporation plc today announced that Aaron Berg, Amarin’s Interim President and Chief Executive Officer and Tom Reilly,... | June 1, 2023
Clearbridge Investments LLC lowered its stake in shares of Amarin Co. plc (NASDAQ:AMRN – Get Rating) by 4.2% during the fourth quarter, Holdings Channel reports. The fund owned 535,234 shares of the biopharmaceutical company’s stock after selling 23,480 shares during the period. Clearbridge Investments LLC’s holdings in Amarin were worth $648,000 as of its most […]